Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Oncolytic viruses encoding bispecific antibodies for the treatment of ovarian cancers
FY 2021-22
Summary
Ovarian
cancer (OCa) has the highest mortality rate of all gynecologic cancers.
Despite extensive testing of cancer therapies in preclinical and clinical
trials, there have been no new treatments that significantly lengthen
survival of OCa patients in more than 30 years. Currently, surgical
resection in combination with chemotherapy provides the only potential
long-term cure for OCa, however most women experience cancer recurrence
within a few years due to drug resistance. There
is a clear unmet need for developing tailored and more effective
treatments for OCa. One of the most active areas of research to overcome
treatment resistance is the use of combinatorial approaches aimed at
stimulating the patient’s immune system to fight against cancer cells
while also inducing a potent and selective toxic effect in the tumor.
Successful execution of this project will lead to the generation of a
oncolytic virus (OV) platform equipped with bispecific T-cell engagers
(BiTEs) that is suited not only to kill OCa cells but also to sensitize
the tumor environment to the killing activity of immune cells while
remaining safe. We expect that the combination of virus-based
immunotherapy and therapeutic cargoes expressed from the virus will be an
effective two-pronged attack that enhances direct killing of cancer cells.
This should indirectly break the tolerance of the patient’s immune system
for the ovarian tumor leading to a novel and potentially more effective
therapeutic approach for women with OCa.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
475262
Name
Vallati Sydney C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Oncolytic viruses encoding bispecific antibodies for the treatment of ovarian cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bispecific T-Cell Engager; Cancer Immunotherapy; Cancer-Associated Fibroblasts (Caf); Epidermal Growth Factor Receptor (Egfr); Fibroblast Activation Protein (Fap); Oncology; Oncolytic Virus; Ovarian Cancer
Abstract
<html>
<head>
</head>
<body>
<span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none"><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px">Ovarian
cancer (OCa) has the highest mortality rate of all gynecologic cancers.
Despite extensive testing of cancer therapies in preclinical and clinical
trials, there have been no new treatments that significantly lengthen
survival of OCa patients in more than 30 years. Currently, surgical
resection in combination with chemotherapy provides the only potential
long-term cure for OCa, however most women experience cancer recurrence
within a few years due to drug resistance.</font></span><font color="rgb(0, 0, 0)" face="Verdana, Arial, Helvetica, sans-serif" size="12.8px"><br align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255)"><span align="start" style="letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); display: inline !important; float: none">There
is a clear unmet need for developing tailored and more effective
treatments for OCa. One of the most active areas of research to overcome
treatment resistance is the use of combinatorial approaches aimed at
stimulating the patient’s immune system to fight against cancer cells
while also inducing a potent and selective toxic effect in the tumor.
Successful execution of this project will lead to the generation of a
oncolytic virus (OV) platform equipped with bispecific T-cell engagers
(BiTEs) that is suited not only to kill OCa cells but also to sensitize
the tumor environment to the killing activity of immune cells while
remaining safe. We expect that the combination of virus-based
immunotherapy and therapeutic cargoes expressed from the virus will be an
effective two-pronged attack that enhances direct killing of cancer cells.
This should indirectly break the tolerance of the patient’s immune system
for the ovarian tumor leading to a novel and potentially more effective
therapeutic approach for women with OCa.</span></font>
</body>
</html>
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vallati, Sydney C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~